In order to investigate the potential role of CaMKII in the cardioprotective effects of SGLT2 inhibition we deployed a model of T2D where CaMKII is established to promote myocardial dysfunction and AF induction. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.